Singapore (VNA) - Singapore has recently approved Pfizer'sComirnaty COVID-19 vaccine for use on children aged six months to four years.
In a statement, the Health Sciences Authority (HSA) said ithad carefully considered the clinical data and assessed that the benefitsoutweighed the risks in administering the vaccine to children in this agegroup.
The vaccination regimen for the primary series in this agegroup will consist of three 3 microgram doses - the first two to beadministered three weeks apart, followed by a third dose to be administered atleast eight weeks after the second dose, said the agency.
Official vaccination recommendations on the use of this vaccine will be issuedby the Expert Committee on COVID-19 Vaccination and the Ministry of Health whenready.
The authority also said that it had consulted experts from itsMedicines Advisory Committee and Panel of Infectious Diseases Experts in makingthe decision.
This is the second vaccine authorised for use in Singaporeby HSA for young children, after the Spikevax vaccine from Moderna.
The Spikevax vaccine was authorised for use on children agedsix months to 17 years on August 24./.
In a statement, the Health Sciences Authority (HSA) said ithad carefully considered the clinical data and assessed that the benefitsoutweighed the risks in administering the vaccine to children in this agegroup.
The vaccination regimen for the primary series in this agegroup will consist of three 3 microgram doses - the first two to beadministered three weeks apart, followed by a third dose to be administered atleast eight weeks after the second dose, said the agency.
Official vaccination recommendations on the use of this vaccine will be issuedby the Expert Committee on COVID-19 Vaccination and the Ministry of Health whenready.
The authority also said that it had consulted experts from itsMedicines Advisory Committee and Panel of Infectious Diseases Experts in makingthe decision.
This is the second vaccine authorised for use in Singaporeby HSA for young children, after the Spikevax vaccine from Moderna.
The Spikevax vaccine was authorised for use on children agedsix months to 17 years on August 24./.
VNA